Articles by Leah Sherwood
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
These prospective results establish FLT3-ITD mutations as essential markers of MRD, the authors wrote.
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
The study also explored the role of this combination in transitioning patients to HSCT.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.
Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist.
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.